^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

DRD2 antagonist

5d
New P1 trial
7d
Effects of Oxygen-Permeable Plates on Cytochrome P450 and Flavin-Containing Monooxygenase in HepaRG Spheroid Cultures. (PubMed, Biol Pharm Bull)
Using clozapine, a low-clearance antipsychotic drug with limited metabolic elimination that is metabolized by monooxygenases, including CYP3A4 and flavin-containing monooxygenase (FMO), we observed an enhanced decline in clozapine levels in PMP plates compared with the clozapine levels seen in the conventional polystyrene plates...These results suggest that improved oxygenation enhances hepatic functionality in 3D cultures by maintaining cell viability and promoting the expression of drug-metabolizing enzymes. Therefore, the PMP plate-based spheroid model offers a practical and physiologically relevant platform for investigating drug metabolism and hepatotoxicity.
Journal
|
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
9d
Striatal Nitric Oxide Activity Better Predicts Motor Disability Than Proto-Oncogenes. (PubMed, Eur J Neurosci)
The aim of the present study was to evaluate whether catalepsy and motor balance deficits resulting from specific acute doses of haloperidol (Hal), metoclopramide (MCP), and L-NOARG could correlate with changes in the number of c-Fos-IR and nNOS-positive cells, as well as NADPH-diaphorase activity in the striatum. In conclusion, all drugs acutely induced catalepsy, with motor balance preserved after L-NOARG treatment. Our findings suggest that EPS side effects may be attributed to NADPH-diaphorase activity in the dorsal striatum.
Journal
|
FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
9d
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201 (clinicaltrials.gov)
P1, N=36, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Mar 2026 --> May 2027
Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
Modeyso (dordaviprone)
10d
Histological Evidence of familial GH-PitNET Associated with Germline MAX Mutation. (PubMed, Eur J Endocrinol)
Despite multimodal therapy (lanreotide, cabergoline, two debulking surgeries), disease control was achieved only after pasireotide and adjuvant proton therapy. The same variant was found in her father, who had a smaller intrasellar macroadenoma causing acromegaly. This familial observation provides the functional evidence that MAX is a driver in GH-PitNET and a candidate gene for PitNET predisposition.
Journal
|
MAX (MYC Associated Factor X)
|
Signifor (pasireotide)
13d
New P3 trial
21d
ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD) (clinicaltrials.gov)
P1, N=48, Completed, Engrail Therapeutics INC | Recruiting --> Completed
Trial completion
23d
Giant Prolactinoma: Challenges in Management. (PubMed, AACE Endocrinol Diabetes)
First-line medical management includes dopamine agonists such as cabergoline and bromocriptine. The dilemma between medical management and surgical management occurs during initial presentation of giant prolactinoma with VF defect. Our case report highlights the challenges and complications encountered in the treatment of a patient with giant prolactinoma.
Journal
|
PRL (Prolactin)
27d
Drug Development. (PubMed, Alzheimers Dement)
OLN significantly improves memory and antioxidant levels while reducing cytokine levels, although its effects on kidney function are limited. These results underscore the intricate relationship between OLN, cognitive function, and renal health.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CAT (Catalase)
|
olanzapine
28d
Association between olanzapine and immune function in lung cancer patients with anxiety and depression: a retrospective cohort study of medical records. (PubMed, Front Psychiatry)
Post-treatment, the treatment group's SDS scores decreased from 42.64 ± 6.32 to 37.06 ± 8.34 (P<0.001), and SAS scores dropped from 50.48 ± 12.94 to 43.61 ± 13.47 (P<0.001). Anxiety and depression impair immune function in lung cancer patients, while olanzapine enhances CD3, CD4, and NK cell activity and reduces psychological distress, suggesting its potential as an adjunct in cancer immunotherapy.
Retrospective data • Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
olanzapine
1m
IRF2BPL transcriptionally regulates IGFBP2 to promote tumor progression and suppresses immune cell infiltration in esophageal squamous cell carcinoma. (PubMed, Oncogene)
Moreover, the chemical drug ONC201 was shown to effectively impede ESCC progression induced by the hyperactive IRF2BPL-IGFBP2 axis in tumor cells. Collectively, our findings verified that the IRF2BPL-IGFBP2 axis plays a critical role in enhancing ESCC progression by increasing the malignancy of ESCC cells and fostering an immune-deficient tumor microenvironment. Targeting the IRF2BPL-IGFBP2 axis may represent a promising therapeutic strategy for ESCC.
Journal
|
IGFBP2 (Insulin-like growth factor binding protein 2)
|
Modeyso (dordaviprone)
1m
ONC206-001: Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms (clinicaltrials.gov)
P1, N=102, Recruiting, Jazz Pharmaceuticals | Trial primary completion date: Dec 2025 --> Jul 2026
Trial primary completion date • First-in-human
|
JZP3507